Spyre Therapeutics Inc. stocks have been trading up by 14.9 percent after positive clinical progress fueled strong investor optimism.
Key Takeaways
- Part A of the Phase 2 SKYLINE trial for SPY002 in ulcerative colitis hit its main goal, with strong remission and endoscopic gains plus class-consistent safety.
- Deutsche Bank lifted its Spyre Therapeutics target to $115 after rival Abivax reported a malignancy safety signal in Phase 3, boosting the perceived runway for SYRE.
- Wedbush raised its SYRE target to $100, seeing class-consistent efficacy and no new safety issues, while the Street’s average target sits near $96 against a share price in the low $80s.
- BTIG moved its Spyre Therapeutics target to $112, increasing modeled success odds across TL1A assets in ulcerative colitis, Crohn’s disease, and rheumatoid arthritis.
- Full enrollment of the SPY072 SKYWAY Phase 2 basket trial keeps six 2026 readouts on track, reinforcing SYRE’s execution story in large rheumatic markets.
Live Update At 14:32:55 EDT: On Monday, June 22, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 14.9%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Spyre Therapeutics, trading under ticker SYRE, has been acting like a textbook biotech momentum name. On 2026/06/22, SYRE closed around $101.50 after tagging an intraday high near $101.71, extending a multi-week uptrend from late May closes in the low $70s. That’s roughly a 35% climb in less than a month, driven by clinical wins and back-to-back analyst target hikes.
The daily chart shows a stair-step pattern: SYRE bounced from about $69 on 2026/06/02 to the high $80s by 2026/06/18, then pushed through $100 with expanding ranges. Intraday on the latest session, five‑minute candles reveal steady higher lows from the mid‑$90s into the close, a sign of dip buyers supporting the move rather than a blow‑off spike.
More Breaking News
- SMR Stock Holds Support As Traders Watch Volatility
- CarMax Stock Jumps As Q1 Beat Triggers Analyst Upgrades
- CDT Equity Rallies As Quantum Bet And Patent Wins Draw Traders
- CERT Stock Slides As Certara Faces Probes And CFO Exit
Under the hood, Spyre Therapeutics is still a classic development‑stage biotech. SYRE posted a quarterly net loss of about $69M and negative operating cash flow near $57M, funding heavy R&D of roughly $60M. Cash and short‑term investments are sizable at about $741M, backed by a strong current ratio near 9 and zero long‑term debt. For traders, that balance sheet means SYRE has runway to fund trials, but the negative returns on equity and assets remind everyone this is a story stock driven by data and headlines, not earnings.
Why Traders Are Watching SYRE Right Now
The real spark for SYRE is the science and how Wall Street is reacting to it. Spyre Therapeutics announced that Part A of its Phase 2 SKYLINE trial in ulcerative colitis hit the primary endpoint for SPY002. The drug delivered statistically significant reductions in RHI score, plus high clinical remission and endoscopic improvement rates, with safety in line with the TL1A class. For biotech traders, that’s your proof‑of‑concept moment: the mechanism works, and it looks tolerable.
As soon as that data hit, the analyst community moved fast. Wedbush raised its SYRE price target to $100 from $80 and reiterated an Outperform rating, noting class‑consistent efficacy and no new safety signals. They highlighted that the average Street target sits around $96 while SYRE shares had been trading in the low $80s, signaling clear upside on paper.
BTIG followed by bumping its Spyre Therapeutics target from $98 to $112. More important than the number, BTIG raised modeled probabilities of success not just for SPY002 in ulcerative colitis, but for the whole TL1A pipeline—covering Crohn’s disease and rheumatoid arthritis—and even lowered its discount rate. That’s a big statement about confidence in the platform.
Deutsche Bank added fuel by taking its SYRE target to $115, calling out an expanded opportunity after Abivax, a competitor in ulcerative colitis, reported a malignancy safety signal in Phase 3. When a rival stumbles on safety, capital often rotates toward the cleaner story. Here, that’s Spyre Therapeutics.
On top of IBD, Spyre has fully enrolled its SKYWAY Phase 2 basket trial of SPY072 across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Six Phase 2 readouts are scheduled for 2026, setting up a steady news pipeline that can keep SYRE in day‑trading and swing‑trading watchlists.
Conclusion
For active traders, SYRE now sits at the intersection of hot data, strong sentiment, and clear technical momentum. Spyre Therapeutics just delivered a positive Phase 2 signal for SPY002 in ulcerative colitis, then watched Deutsche Bank, Wedbush, and BTIG race to raise their price targets into the $100–$115 range. At the same time, SYRE’s chart reflects that optimism, with a clean trend from the low $70s to above $100 and intraday action showing buyers stepping in on every pullback.
But this is still a loss‑making biotech leaning on a large cash pile and a TL1A thesis. The business lives and dies on future readouts from SKYLINE and SKYWAY, and on how the Street updates models after each data point. Traders in SYRE need to respect that binary nature, the same way they would with any development‑stage name.
As Tim Sykes likes to remind his students, “The market doesn’t care about your opinion, only about price action and catalysts.” As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. For Spyre Therapeutics and SYRE, the catalysts are real, the price action is hot, and the key now is to trade the plan—study the chart, know the dates, and cut losses fast if the story changes. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply